New action plan to foster development of advanced therapies
Actions address specific challenges identified by stakeholders
The European Commission's Directorate-General for Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA) recently published a joint action plan to foster the development of advanced therapy medicinal products (ATMPs). The main aim is to streamline procedures and better address the specific requirements of ATMP developers.
ATMPs are medicines for human use that are based on genes or cells. These therapies offer ground-breaking new opportunities for the treatment of disease and injury. They are particularly important for severe, untreatable or chronic diseases for which conventional approaches have proven to be inadequate.
ATMPs can be classified into four main groups: gene therapy medicinal products, somatic cell therapy medicinal products, tissue engineered medicinal products and combined ATMPs. EMA has received 18 marketing authorisation applications since the ATMP regulation came into force in 2009. Nine products have been approved.
The Agency's Committee for Advanced Therapies (CAT) plays a central role in the scientific assessment of ATMPs, as it provides the expertise needed to evaluate these medicines. Other initiatives include European Commission research programmes, the innovation offices in the national competent authorities and EMA’s PRIME scheme.
At international level, a regular forum for dialogue has been set up with the United States Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to share experience on ATMPs. EMA and the CAT also contribute to the cell therapy group and gene therapy groupof the International Pharmaceutical Regulators’ Forum (IPRF).
DG SANTE and EMA, in collaboration with the Member States' competent authorities, are working on some initiatives to support the development and authorisation of high quality, safe and effective ATMPs. The plan published today contains 19 actions in different key areas. Some of the actions are already in place, others are new. Actions were also informed by the ideas collected during a multi-stakeholder workshop hosted by EMA on 27 May 2016. The workshop aimed to explore solutions to identified challenges in the development of ATMPs. Topics discussed ranged from the need for early interaction and guidance from regulators, to more transparency and information sharing, greater harmonisation between Member States in various aspects of ATMP regulation and measures to tackle inequalities in patient access to ATMP treatments.
Examples of upcoming actions in the plan include:
- European Commission guideline on good manufacturing practice for ATMPs, to reduce the administrative burden and adapt the manufacturing requirements to the specific characteristics of ATMPs;
- initiation of dialogue with national competent authorities to address the interplay between the legislation on genetically modified organisms (GMO) and on medicines,to reduce discrepancies across the European Union (EU) regarding the application of GMO rules;
- new EMA scientific guidelines on ATMPs, including investigational ATMPs, to clarify regulatory expectations;
- continuous awareness and training sessions organised by EMA for the EU network on ATMP-related topics.
DG SANTE and EMA will continue monitoring the field and propose further initiatives as appropriate.
- Advanced therapies: research & development
- Advanced theraoies: overview
- Committee for Advanced Therapies (CAT)
- Multi-stakeholder advanced therapy medicinal products (ATMPs) expert meeting: exploring solutions to foster ATMPs’ development and patient access in Europe (27/5/2016)
Latest News from
Opening remarks by President von der Leyen at the civil society consultation ahead of the Global Health Summit21/04/2021 12:38:00
Opening remarks given yesterday by President von der Leyen at the civil society consultation ahead of the Global Health Summit.
Road safety: 4,000 fewer people lost their lives on EU roads in 2020 as death rate falls to all-time low21/04/2021 11:33:00
The European Commission yesterday published preliminary figures on road fatalities for 2020. An estimated 18,800 people were killed in a road crash last year, an unprecedented annual fall of 17% on 2019.
The European Commission and Austria secure COVID-19 vaccines for the Western Balkans21/04/2021 10:38:00
The European Commission and Austria yesterday announced the conclusion of agreements for the delivery of COVID-19 vaccines for the Western Balkans.
New Commission Knowledge Centre on Earth Observation to further strengthen evidence-based policymaking21/04/2021 09:25:00
The Commission has launched a Knowledge Centre on Earth Observation, to maximise the use of knowledge generated from Earth Observation, in particular from the European Copernicus Programme, in EU policymaking.
EU launches €100 million humanitarian initiative to support COVID-19 vaccination campaigns in Africa20/04/2021 16:38:00
Today, Commissioner for Crisis Management, Janez Lenarčič, will visit the Africa Centres for Disease control and Prevention (Africa CDC) in Addis Ababa.
Justice, rights and values: Council adopts programmes of up to €1.8 billion for 2021-202720/04/2021 15:25:00
The Council yesterday adopted the two programmes which constitute the EU justice, rights and values fund as part of the EU financial framework for 2021-2027.
State aid: Commission adopts revised Regional Aid Guidelines20/04/2021 14:33:00
The European Commission has adopted revised EU guidelines on regional State aid (the “Regional Aid Guidelines”), setting out the rules under which Member States can grant State aid to companies to support the economic development of disadvantaged areas in the EU, while ensuring a level playing field between Member States.
Council adopts position on €14.8 billion EU space programme for 2021-202720/04/2021 13:25:00
The Council yesterday adopted its first reading position on the proposed regulation establishing the EU space programme (“the programme”) for the years 2021 to 2027.
Conference on the Future of Europe: launch of the multilingual digital platform20/04/2021 11:25:00
The Executive Board of the Conference on the Future of Europe, comprising representatives from the European Parliament, the Council of the European Union and the European Commission, is launching the multilingual digital platform for the Conference on the Future of Europe inviting all EU citizens to contribute to shaping their own future and that of Europe as a whole.